Abstract: Disclosed herein are compositions and methods for treating and/or preventing cancer in mammals, and in particular, vaccines that treat and provide protection against tumor growth.
Type:
Grant
Filed:
June 7, 2018
Date of Patent:
April 2, 2024
Assignee:
The Wistar Institute of Anatomy and Biology
Abstract: Disclosed herein is a composition comprising a recombinant nucleic acid sequence that encodes an antibody to a Zika viral antigen, and functional fragments thereof. The invention also relates to a composition comprising the combination of a first composition that elicits an immune response in a mammal against zika virus and a second composition comprising a recombinant nucleic acid sequence encoding an antibody, a fragment thereof, a variant thereof, or a combination thereof. In some instances, the nucleic acid molecule comprises a nucleotide sequence encoding an anti-ZIKV-Envelope (anti-ZIKV E) Protein antibody.
Type:
Grant
Filed:
September 19, 2017
Date of Patent:
March 12, 2024
Assignees:
The Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc., The Wistar Institute of Anatomy and Biology
Inventors:
David Weiner, Karuppiah Muthumani, Jian Yan
Abstract: The present invention provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by EBNA1 activity, such as, but not limited to, cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and/or rheumatoid arthritis. The present invention further provides EBNA1 inhibitors, and/or pharmaceutical compositions comprising the same, that are useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection and/or lytic EBV infection.
Type:
Grant
Filed:
April 16, 2021
Date of Patent:
February 27, 2024
Assignee:
The Wistar Institute of Anatomy and Biology
Inventors:
Troy E. Messick, Garry R. Smith, Allen B. Reitz, Paul M. Lieberman, Mark E. McDonnell, Yan Zhang, Marianne Carlsen, Shuai Chen
Abstract: Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody or fragment thereof that targets an immune checkpoint molecule. The disclosure also provides a method of preventing and/or treating disease in a subject using said composition and method of generation.
Type:
Grant
Filed:
May 5, 2017
Date of Patent:
February 13, 2024
Assignees:
The Trustees of the University of Pennsylvania, The Wistar Institute of Anatomy and Biology, Inovio Pharmaceuticals
Inventors:
David B. Weiner, Kar Muthumani, Niranjan Sardesai
Abstract: The present invention relates to compositions comprising two or more DNA plasmids encoding consensus and transmitted founder HIV envelope glycoproteins which expressed and induce a potent immune response.
Type:
Grant
Filed:
November 10, 2020
Date of Patent:
January 30, 2024
Assignees:
The Trustees of the University of Pennsylvania, The Wistar Institute of Anatomy and Biology
Abstract: The present disclosure provide for methods of using 6-thio-2?-deoxyguanosine (6-thio-dG) to treat telomerase-positive cancers that exhibit (a) one or more TERT promoter mutations, and/or (b) enriched telomere transcriptional signature(s). In particular, melanomas, including those who are not sensitive or have become resistant to immune checkpoint inhibition and/or MAPKi therapy are targets for this therapy.
Type:
Application
Filed:
June 5, 2023
Publication date:
January 11, 2024
Applicants:
The Board of Regents of The University of Texas System, The Wistar Institute of Anatomy and Biology
Abstract: Provided herein is an immunogenic composition comprising a synthetic consensus antigen to Follicle Stimulating Hormone Receptor (FSHR) protein which is abundant in many ovarian cancer sub-types. Also disclosed herein is a method of treating a tumor associated pathology in a subject in need thereof, by administering the immunogenic composition to the subject.
Type:
Grant
Filed:
August 29, 2017
Date of Patent:
January 9, 2024
Assignees:
The Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc., The Wistar Institute of Anatomy and Biology
Inventors:
David Weiner, Alfredo Perales Puchalt, Jian Yan, Anna Maria Slager
Abstract: Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an anti-influenza-hemagglutinin synthetic antibody. The disclosure also provides a method of preventing and/or treating influenza in a subject using said composition and method of generation.
Type:
Grant
Filed:
May 5, 2017
Date of Patent:
December 26, 2023
Assignees:
The Trustees of the University of Pennsylvania, The Wistar Institute of Anatomy and Biology, Inovio Pharmaceuticals, Inc.
Inventors:
David B. Weiner, Ami Patel, Jian Yan, Sarah Elliott
Abstract: Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody to an HIV antigen. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating an HIV infection in a subject using said composition and method of generation.
Type:
Grant
Filed:
March 27, 2018
Date of Patent:
December 19, 2023
Assignees:
The Wistar Institute of Anatomy and Biology, Inovio Pharmaceuticals, Inc.
Abstract: Disclosed are compositions comprising an expressible nucleic acid sequence comprising a first nucleic acid sequence comprising a sequence that encodes an adjuvant polypeptide or a pharmaceutically acceptable salt thereof and a second nucleic acid sequence comprising a sequence that encodes an antigen from a virus or from a cancer. In some embodiments, the expressible nucleic acid sequence further comprises a nucleic acid sequence encoding at least one viral antigen or a pharmaceutically acceptable salt thereof. In some embodiments, the expressible nucleic acid sequence further comprises at least one nucleic acid sequence encoding a linker.
Type:
Application
Filed:
June 30, 2021
Publication date:
September 14, 2023
Applicant:
THE WISTAR INSTITUTE OF ANATOMY & BIOLOGY
Inventors:
Ziyang XU, Daniel W. KULP, David B. WEINER
Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention relates to targeting the stromal cell population in a tumor microenvironment. For example, in one embodiment, the invention provides a composition that is targeted to fibroblast activation protein (FAP). The invention includes a chimeric antigen receptor (CAR) which comprises an anti-FAP domain, a transmembrane domain, and a CD3zeta signaling domain.
Type:
Grant
Filed:
May 20, 2019
Date of Patent:
August 8, 2023
Assignees:
The Trustees of the University of Pennsylvania, The Wistar Institute of Anatomy and Biology
Inventors:
Carl H. June, Ellen Pure, Liang-Chuan Wang, Steven Albelda, John Scholler
Abstract: The present disclosure is directed to the use of IRE-1 and/or XBP-1 inhibitors to treat cancers having mutations in ARID 1 A over overexpressing CARM1.
Type:
Application
Filed:
February 26, 2021
Publication date:
June 15, 2023
Applicant:
The Wistar Institute of Anatomy and Biology
Inventors:
Rugang ZHANG, Joseph ZUNDELL, Jianhuang LIN
Abstract: Disclosed herein are nucleic acid molecules encoding a SARS-CoV-2 spike antigen, SARS-CoV-2 spike antigens, immunogenic compositions, and vaccines and their use in inducing immune responses and protecting against or treating a Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) infection in a subject.
Type:
Grant
Filed:
February 25, 2021
Date of Patent:
May 30, 2023
Assignees:
Inovio Pharmaceuticals, Inc., The Wistar Institute of Anatomy and Biology
Inventors:
Jian Yan, Kate Broderick, David Weiner, Kar Muthumani, Ami Patel
Abstract: Methods and compositions are provided for diagnosing lung cancer in a mammalian subject by use of 10 or more selected genes, e.g., a gene expression profile, from the blood of the subject which is characteristic of disease. The gene expression profile includes 10 or more genes of Table I or Table II herein.
Type:
Grant
Filed:
June 21, 2017
Date of Patent:
May 30, 2023
Assignee:
The Wistar Institute of Anatomy and
Biology
Inventors:
Michael Showe, Louise C. Showe, Andrei V. Kossenkov
Abstract: An aspect of the present invention is related to nucleic acid constructs capable of expressing a Zika antigen that elicits an immune response in a mammal against Zika virus, and methods of use thereof. Additionally, there are DNA plasmid vaccines capable of generating in a mammal an immune response against a Zika virus, comprising a DNA plasmid and a pharmaceutically acceptable excipient, and methods of use thereof. The DNA plasmid is capable of expressing a Zika antigen in a cell of the mammal in a quantity effective to elicit an immune response in the mammal that is cross reactive against all Zika strains.
Type:
Grant
Filed:
February 24, 2017
Date of Patent:
May 16, 2023
Assignees:
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY
Abstract: Nucleic acid molecules and compositions comprising one or more nucleotide sequences that encode a consensus Merkel Cell Polyomavirus (MCV) T antigen. Immunomodulatory methods and methods of inducing an immune response against MCV are disclosed. Method of treating infection by MCV and methods of treating or preventing Merkel Cell Carcinoma associated with MCV are disclosed. Modified consensus MCV T antigens are disclosed.
Type:
Grant
Filed:
January 18, 2019
Date of Patent:
December 13, 2022
Assignee:
THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY
Abstract: The present disclosure is directed to the use of inhibitors of glutamate metabolism to treat cancers that have mutations in ARID1A. Thus, in accordance with the present disclosure, there is provided a method of treating a subject determined to have an ARIDIA-mutated cancer, pre-cancer or benign tumor comprising administering to said subject at least one inhibitor of glutamate metabolism.
Type:
Application
Filed:
September 11, 2020
Publication date:
November 3, 2022
Applicant:
The Wistar Institute of Anatomy and Biology
Abstract: Disclosed herein are compositions comprising optimized consensus TERT antigens and methods for treating cancer and in particular immunogenic compositions that treat and provide protection against tumor.
Type:
Grant
Filed:
September 29, 2017
Date of Patent:
October 11, 2022
Assignees:
The Trustees of the University of Pennsylvania, The Wistar Institute of Anatomy and Biology, Inovio Pharmaceuticals, Inc.
Abstract: Nucleic acid molecules and compositions comprising one or more nucleotide sequences that encode a consensus Epstein-Barr virus (EBV) antigen. Immunomodulatory methods and methods of inducing an immune response against EBV are disclosed. Method of treating infection by EBV and methods of treating or preventing a disease or disorder associated with EBV are disclosed. Modified consensus EBV antigens are disclosed.
Type:
Grant
Filed:
February 15, 2019
Date of Patent:
July 26, 2022
Assignee:
THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY